Constantinos Alifieris

1.3k total citations · 1 hit paper
15 papers, 998 citations indexed

About

Constantinos Alifieris is a scholar working on Oncology, Molecular Biology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Constantinos Alifieris has authored 15 papers receiving a total of 998 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Oncology, 6 papers in Molecular Biology and 3 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Constantinos Alifieris's work include DNA Repair Mechanisms (2 papers), Neuroendocrine Tumor Research Advances (2 papers) and Cancer Treatment and Pharmacology (2 papers). Constantinos Alifieris is often cited by papers focused on DNA Repair Mechanisms (2 papers), Neuroendocrine Tumor Research Advances (2 papers) and Cancer Treatment and Pharmacology (2 papers). Constantinos Alifieris collaborates with scholars based in Greece, Cyprus and United States. Constantinos Alifieris's co-authors include Dimitrios T. Trafalis, Anastasia Constantinidou, George D. Geromichalos, George P. Stathopoulos, Nikolaos M. Sitaras, Dimitrios Krikelis, Chrysovalantis Vergadis, Sébastien Sauvage, Athanasios Tampakis and Anastasia Pazaiti and has published in prestigious journals such as Pharmacology & Therapeutics, Cancer Chemotherapy and Pharmacology and Journal of Cancer Research and Clinical Oncology.

In The Last Decade

Constantinos Alifieris

13 papers receiving 991 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Glioblastoma multiforme: Pathogenesis and treatment

2015 603 citations Constantinos Alifieris, Dimitrios T. Trafalis Pharmacology & Therapeutics profile →

Peers

Constantinos Alifieris

ONCOL

GENET

IMMUN

Andrea Shergalis United States

Ke Sai China

Mariachiara Buccarelli Italy

Ozlem Aksoy United States

Sara Granja Portugal

Yuan Rong China

Felix Zeppernick Germany

Heekyoung Yang South Korea

Andrea Shergalis United States

Constantinos Alifieris

508 ×1.3

123 ×0.4

ONCOL

192 ×0.9

217 ×1.0

GENET

90 ×0.5

IMMUN

Citations per year, relative to Constantinos Alifieris Constantinos Alifieris (= 1×) peers Andrea Shergalis

Countries citing papers authored by Constantinos Alifieris

Since Specialization

Citations

This map shows the geographic impact of Constantinos Alifieris's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Constantinos Alifieris with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Constantinos Alifieris more than expected).

Fields of papers citing papers by Constantinos Alifieris

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Constantinos Alifieris. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Constantinos Alifieris. The network helps show where Constantinos Alifieris may publish in the future.

Co-authorship network of co-authors of Constantinos Alifieris

This figure shows the co-authorship network connecting the top 25 collaborators of Constantinos Alifieris. A scholar is included among the top collaborators of Constantinos Alifieris based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Constantinos Alifieris. Constantinos Alifieris is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

15 of 15 papers shown

Alifieris, Constantinos, et al.. (2025). Predictive value of 8-hydroxy-2′-deoxyguanosine and 8-nitroguanine production in radiation-induced skin damage after postoperative breast cancer radiotherapy. Exploration of Targeted Anti-tumor Therapy. 6. 1002336–1002336.

Alifieris, Constantinos, et al.. (2024). The Predictive Value of 8-Hydroxy-Deoxyguanosine (8-OHdG) Serum Concentrations in Irradiated Non-Small Cell Lung Carcinoma (NSCLC) Patients. Biomedicines. 12(1). 134–134. 6 indexed citations

Dalezis, Panagiotis, et al.. (2021). Cytocidal Antitumor Effects against Human Ovarian Cancer Cells Induced by B-Lactam Steroid Alkylators with Targeted Activity against Poly (ADP-Ribose) Polymerase (PARP) Enzymes in a Cell-Free Assay. Biomedicines. 9(8). 1028–1028. 3 indexed citations

Alifieris, Constantinos, et al.. (2021). The arbitrary magic of p<0.05: Beyond statistics.. PubMed. 25(2). 588–593.

Alifieris, Constantinos, John Grınıatsos, Spiros Delis, et al.. (2020). Capecitabine, Oxaliplatin, Irinotecan, and Bevacizumab Combination Followed by Pazopanib Plus Capecitabine Maintenance for High-Grade Gastrointestinal Neuroendocrine Carcinomas. American Journal of Clinical Oncology. 43(5). 305–310. 11 indexed citations

Tampaki, Ekaterini Christina, Athanasios Tampakis, Constantinos Alifieris, et al.. (2018). Efficacy and Safety of Neoadjuvant Treatment with Bevacizumab, Liposomal Doxorubicin, Cyclophosphamide and Paclitaxel Combination in Locally/Regionally Advanced, HER2-Negative, Grade III at Premenopausal Status Breast Cancer: A Phase II Study. Clinical Drug Investigation. 38(7). 639–648. 28 indexed citations

Constantinidou, Anastasia, Constantinos Alifieris, & Dimitrios T. Trafalis. (2018). Targeting Programmed Cell Death -1 (PD-1) and Ligand (PD-L1): A new era in cancer active immunotherapy. Pharmacology & Therapeutics. 194. 84–106. 260 indexed citations

Trafalis, Dimitrios T., et al.. (2018). Evidence for Efficacy of Treatment With the Anti-PD-1 Mab Nivolumab in Radiation and Multichemorefractory Advanced Penile Squamous Cell Carcinoma. Journal of Immunotherapy. 41(6). 300–305. 30 indexed citations

Alifieris, Constantinos, et al.. (2017). A retrospective open-label uncontrolled study of Epoetin zeta on the treatment of chemotherapy-induced anemia in solid tumors. Journal of Cancer Research and Clinical Oncology. 143(4). 717–725. 3 indexed citations

10.

Geromichalos, George D., et al.. (2017). Overview on the current status of virtual high-throughput screening and combinatorial chemistry approaches in multi-target anticancer drug discovery; Part I.. PubMed. 21(4). 1337–1358. 26 indexed citations

11.

Tampakis, Athanasios, et al.. (2017). Efficacy and safety of neoadjuvant treatment with liposomal doxorubicin, cyclophosphamide, paclitaxel and bevazicumab combination in locally/regionally advanced HER-2 negative, grade III premenopausal status breast cancer. The Breast. 32. S82–S82. 2 indexed citations

12.

Trafalis, Dimitrios T., Constantinos Alifieris, George P. Stathopoulos, & Nikolaos M. Sitaras. (2016). Phase II study of bevacizumab plus irinotecan on the treatment of relapsed resistant small cell lung cancer. Cancer Chemotherapy and Pharmacology. 77(4). 713–722. 19 indexed citations

13.

Alifieris, Constantinos & Dimitrios T. Trafalis. (2015). Glioblastoma multiforme: Pathogenesis and treatment. Pharmacology & Therapeutics. 152. 63–82. 603 indexed citations breakdown →

14.

Trafalis, Dimitrios T., Constantinos Alifieris, Panagiotis Dalezis, George D. Geromichalos, & Nikolaos M. Sitaras. (2012). Indications for an alternative effective treatment of head and neck squamous cell carcinoma with temsirolimus plus bevacizumab. Anti-Cancer Drugs. 23(8). 874–882. 2 indexed citations

15.

Trafalis, Dimitrios T., et al.. (2012). Topotecan and pegylated liposomal doxorubicin combination as palliative treatment in patients with pretreated advanced malignant pleural mesothelioma. International Journal of Clinical Pharmacology and Therapeutics. 50(7). 490–499. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Andrea Shergalis Breakdown of academic impact, for papers by Ke Sai Breakdown of academic impact, for papers by Mariachiara Buccarelli Breakdown of academic impact, for papers by Ozlem Aksoy Breakdown of academic impact, for papers by Sara Granja Breakdown of academic impact, for papers by Yuan Rong Breakdown of academic impact, for papers by Felix Zeppernick Breakdown of academic impact, for papers by Heekyoung Yang